SILVESTRIS, Nicola
 Distribuzione geografica
Continente #
NA - Nord America 12.782
EU - Europa 2.219
AS - Asia 1.305
SA - Sud America 174
AF - Africa 13
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 16.497
Nazione #
US - Stati Uniti d'America 12.737
SE - Svezia 726
RU - Federazione Russa 570
SG - Singapore 563
CN - Cina 508
GB - Regno Unito 179
BR - Brasile 161
IT - Italia 155
FR - Francia 138
BE - Belgio 108
DE - Germania 89
IN - India 69
FI - Finlandia 43
UA - Ucraina 42
ID - Indonesia 38
CZ - Repubblica Ceca 37
VN - Vietnam 35
CA - Canada 31
AT - Austria 17
HK - Hong Kong 15
IR - Iran 14
IE - Irlanda 13
TR - Turchia 12
BG - Bulgaria 11
NL - Olanda 11
ES - Italia 9
JP - Giappone 8
PL - Polonia 8
HR - Croazia 7
AR - Argentina 6
RO - Romania 6
RS - Serbia 6
IL - Israele 5
NO - Norvegia 5
PT - Portogallo 5
UZ - Uzbekistan 5
AL - Albania 4
DK - Danimarca 4
HU - Ungheria 4
LT - Lituania 4
PK - Pakistan 4
AM - Armenia 3
AU - Australia 3
BD - Bangladesh 3
CH - Svizzera 3
KZ - Kazakistan 3
MT - Malta 3
MX - Messico 3
NG - Nigeria 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
BH - Bahrain 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
EG - Egitto 2
GR - Grecia 2
KW - Kuwait 2
LV - Lettonia 2
MA - Marocco 2
PA - Panama 2
PH - Filippine 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
A1 - Anonimo 1
AZ - Azerbaigian 1
BO - Bolivia 1
BS - Bahamas 1
BT - Bhutan 1
CL - Cile 1
CO - Colombia 1
EC - Ecuador 1
GL - Groenlandia 1
HN - Honduras 1
IS - Islanda 1
JM - Giamaica 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MC - Monaco 1
ME - Montenegro 1
NP - Nepal 1
PE - Perù 1
PY - Paraguay 1
SA - Arabia Saudita 1
SV - El Salvador 1
TH - Thailandia 1
TW - Taiwan 1
VE - Venezuela 1
Totale 16.497
Città #
Fairfield 2.057
Chandler 1.769
Ashburn 1.170
Woodbridge 1.034
Cambridge 908
Seattle 908
Houston 817
Wilmington 649
Nyköping 569
Ann Arbor 397
Singapore 387
Lawrence 245
Roxbury 230
Des Moines 146
Beijing 141
Brussels 106
Paris 104
San Diego 97
Inglewood 92
Dearborn 88
New York 86
Jacksonville 78
Council Bluffs 74
Moscow 70
Brooklyn 62
Los Angeles 59
London 54
Pune 54
Bari 52
Boardman 50
Santa Clara 46
Nanjing 40
Jakarta 38
Washington 34
Brno 26
Edinburgh 26
San Mateo 26
Falls Church 23
Helsinki 23
Princeton 23
Dong Ket 22
Ruvo Di Puglia 20
Jinan 19
Munich 19
Monmouth Junction 17
Norwalk 17
Hefei 16
Shanghai 16
Guangzhou 15
Vienna 15
Augusta 14
Dublin 13
Grafing 13
Jiaxing 13
Marseille 13
Leawood 11
Prescot 11
Zhengzhou 11
Chicago 10
Nanchang 10
Shenyang 10
Sofia 10
Toronto 10
Ardabil 9
Frankfurt am Main 9
Hanoi 9
Hong Kong 9
Kilburn 9
Kunming 8
Olomouc 8
Ottawa 8
Amsterdam 7
Dallas 7
Hebei 7
Madrid 7
Stockholm 7
São Paulo 7
Tokyo 7
Warsaw 7
Zagreb 7
Atlanta 6
Belgrade 6
Belo Horizonte 6
Changsha 6
Chiswick 6
Hounslow 6
Miami 6
Montreal 6
Ningbo 6
Nuremberg 6
Rome 6
San Francisco 6
Tianjin 6
Cinisello Balsamo 5
Milan 5
Mumbai 5
New Bedfont 5
Oslo 5
Redwood City 5
Rio de Janeiro 5
Totale 13.428
Nome #
Mast cells and angiogenesis in pancreatic ductal adenocarcinoma 193
Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells 140
Angiogenesis in adenosquamous cancer of pancreas 135
Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma 134
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 126
Targeting angiogenesis in biliary tract cancers: An open option 124
Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview 120
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue 119
Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study 117
Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma 114
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 113
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. A review of the literature and a long-standing experience of a referral center 107
Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance 106
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 104
IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity 103
Second-line chemotherapy in advanced biliary cancer: The present now will later be past 102
Anti-EGFR monoclonal antibody in cancer treatment: In vitro and in vivo evidence 101
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 100
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 100
How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis 99
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence 99
Metronomic chemotherapy from rationale to clinical studies: A dream or reality? 98
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma 98
Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity 97
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 97
The European accreditation of Istituto Tumori Giovanni Paolo II of Bari 97
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 97
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 96
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 96
Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma 96
Challenges and opportunities of MicroRNAs in lymphomas 96
mTOR as a target of everolimus in refractory/relapsed Hodgkin Lymphoma 96
Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment 95
NHERF1 and tumor microenvironment: A new scene in invasive breast carcinoma 95
The dark side of the moon: The PI3K/PTEN/AKT pathway in colorectal carcinoma 95
Carcinogenesis of pancreatic adenocarcinoma: Precursor lesions 94
Immunotherapeutic approaches for hepatocellular carcinoma 93
Prognostic role of high-grade tumor budding in pancreatic ductal adenocarcinoma: A systematic review and meta-analysis with a focus on epithelial to mesenchymal transition 92
Fas/Fas-ligand (Fas-L)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells 91
Should tumor infiltrating lymphocytes, androgen receptor, and FOXA1 expression predict the clinical outcome in triple negative breast cancer patients? 90
Bone metastases in biliary cancers: A multicenter retrospective survey 90
The coordinated role of CYP450 enzymes and P-gp in determining cancer resistance to chemotherapy 89
Micro-RNA in pancreatic adenocarcinoma: Predictive/prognostic biomarkers or therapeutic targets? 88
Metastatic gastric cancer in the last two decades: Goals achieved and future promises 88
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 87
Antineoplastic drug-induced bradyarrhythmias 87
Adjuvant colon cancer chemotherapy: Where we are and where we'll go 87
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 87
Active treatment given in the last weeks of life: poor quality cancer care or justifiable behavior? 86
Torch study: How much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? 86
Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study 86
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 85
Synthetic lethality to overcome cancer drug resistance 85
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 85
Pharmacokinetic and metabolism determinants of fluoropyrimidines and oxaliplatin activity in treatment of colorectal patients. 85
HER-2 inhibition in gastric and colorectal cancers: Tangible achievements, novel acquisitions and future perspectives 85
p53 as the main traffic controller of the cell signaling network 85
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 84
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study 84
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: Implications for clinical practice 84
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity 84
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 83
The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy 83
Adjuvant therapy in colon cancer 83
Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper 82
Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype 82
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 82
null 81
Oncosuppressor methylation: A possible key role in colon metastatic progression 81
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib 80
High density of tryptase-positive mast cells in human colorectal cancer: A poor prognostic factor related to protease-activated receptor 2 expression 80
null 80
CES2, ABCG2, TS and topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen 80
Target therapies in pancreatic carcinoma 80
The process of truth disclosure: An assessment of the results of information during the diagnostic phase in patients with cancer 80
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 80
Unique case of giant adult paratesticular spindle cell rhabdomyosarcoma 79
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A gruppo oncologico dell'Italia meridionale multicenter phase II study 79
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: From biological principles to clinical guidelines 79
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 79
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 79
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma 78
Combined modality treatments in pancreatic cancer 78
Current status of targeted therapies in advanced gastric cancer 78
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study 78
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: An open issue 77
Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma 77
Molecular classifications of gastric cancers: Novel insights and possible future applications 76
Estimating survival probabilities of advanced gastric cancer patients in the second-line setting: The gastric life nomogram 76
Update on capecitabine alone and in combination regimens in colorectal cancer patients 76
New molecular targets in bone metastases 76
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside 76
Synchronous Mandibular and Giant Parieto-occipital Skull Metastasis From Hepatocellular Carcinoma 75
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 75
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX 75
Systematic review of irreversible electroporation role in management of locally advanced pancreatic cancer 75
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 75
Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report 74
Role of gemcitabine in metastatic breast cancer patients: A short review 74
Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report 73
Totale 9.126
Categoria #
all - tutte 91.278
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.278


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.255 0 0 0 0 0 0 0 711 798 283 333 130
2020/20213.157 229 178 417 369 287 330 206 254 217 285 266 119
2021/20222.210 158 210 40 77 159 151 111 133 142 113 227 689
2022/20233.704 403 517 292 362 319 414 111 475 541 26 204 40
2023/20241.173 84 216 80 103 124 324 19 66 9 28 10 110
2024/20252.117 96 83 364 208 154 517 390 305 0 0 0 0
Totale 17.100